Rgs2 Protein Regulator Of G Protein Signaling 2 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
[^1]
| Parameter | Value | [^2]
|-----------|-------|
| **Protein Name** | Regulator of G Protein Signaling 2 (RGS2) |
| **Gene** | RGS2 |
| **UniProt ID** | P41221 |
| **PDB ID** | 2EBN, 2OEV |
| **Molecular Weight** | 24 kDa |
| **Subcellular Localization** | Plasma membrane, cytoplasm |
| **Protein Family** | RGS family (B8 subfamily) |
RGS2 is a member of the Regulator of G Protein Signaling (RGS) protein family. It functions as a GTPase-activating protein (GAP) that accelerates the intrinsic GTP hydrolysis rate of Gα subunits, thereby acting as a negative regulator of G protein-coupled receptor signaling.
RGS2 has a characteristic RGS domain structure:
- RGS domain: Core catalytic domain (~120 aa)
- N-terminal domain: Regulatory sequences
- GoLoco domain: Present in some RGS proteins
- PDZ-binding motif: For protein-protein interactions
The RGS domain forms a bundle of alpha helices that interacts with the switch regions of Gα subunits.
- GAP activity for Gαq and Gαs subunits
- Rapid signal termination
- Temporal control of GPCR signaling
- Gαq: PLCβ signaling
- Gαs: Adenylate cyclase signaling
- Gαi/o: Some inhibition
- Protein scaffold for signaling complexes
- Localization to membrane microdomains
- Transcriptional regulation
- Cardiovascular function (blood pressure)
- Anxiety and stress responses
- Learning and memory
- Smooth muscle contraction
- Dopamine receptor signaling modulation
- Gαs-coupled receptor effects
- Therapeutic potential
- RGS2 deficiency leads to hypertension
- Increased vascular tone
- Gαq-mediated smooth muscle contraction
- RGS2 knockout mice show anxiety-like behavior
- Modulates GABAergic signaling
- Stress response alterations
| Approach |
Strategy |
Status |
| RGS2 modulators |
Increase expression |
Research |
| GPCR modulators |
Downstream targeting |
Clinical |
| Gene therapy |
Viral delivery |
Preclinical |
- DeVries L, et al. (2000). RGS proteins. Oncogene 19(55):6260-70.
- Hollinger S, et al. (2002). RGS domain structure. Pharmacol Rev 54(3):527-59.
- Berman DM, et al. (1996). RGS function. Cell 86(3):445-52.
The study of Rgs2 Protein Regulator Of G Protein Signaling 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.